Joshua J. Meeks, MD, discusses investigational targets in the bladder cancer space.
Joshua J. Meeks, MD, Edward M. Schaeffer, MD, PhD Professor of Urology, and associate professor of Urology and Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, discusses investigational targets in the bladder cancer space.
One of the most promising targeted in bladder cancer to date is FGFR3, according to Meek. In patients with advanced disease or muscle invasive disease, FGFR3 alterations exists but are less frequent compared with early-stage disease. Meeks said the 40% or more patients with early-stage bladder cancer have FGFR3 alterations.
The unanswered questions physicians have is how to target FGFR3, weigh the benefits, and limit treatment toxicity, explained Meeks.
Breast Cancer Survivors Find Success With Pregnancy After Treatment
May 24th 2024A study offers promising news for young women with early-stage breast cancer who want to have children after treatment, showing that 73% of breast cancer survivors who attempted pregnancy were successful.
Read More